Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 8/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.49 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.49 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035081 | 0.90 | ESR1 (0.57) | ESR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL4197102 | 0.88 | ESR1 (0.44) | ESR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL4029018 | 0.87 | ESR1 (0.51) | ESR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL4033183 | 0.83 | ESR1 (0.51) | ESR1MEN1KMT2APTGER1 | |
| SCHEMBL4032054 | 0.82 | ESR1 (0.61) | ESR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL4030717 | 0.82 | MAPK1 (0.53) | ESR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL4025242 | 0.78 | ESR1 (0.44) | ESR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL4030236 | 0.77 | ESR1 (0.57) | ESR1MAPK1MAP2K4MAPKAPK2MAPKAPK3 | |
| SCHEMBL4027878 | 0.77 | ESR1 (0.63) | ESR1MAPK1MAPTKMT2ACYP1A2 | |
| SCHEMBL4035750 | 0.76 | ESR1 (0.62) | ESR1PTGER1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1542976-B1 | SUBSTITUTED 4-(INDAZOL-3-YL)PHENOLS AS ESTROGEN RECEPTOR (ER) LIGANDS AND THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES | WYETH CORP (US) | 2009-02-04 | — | — | EP | disclosed |
| CN-101054364-A | Substituted 4-(indazol-3-yl)phenols as estrogen receptor (ER) ligands and their use in the treatmentof inflammarory diseases | WYETH CORP (US) | 2007-10-17 | — | — | CN | disclosed |
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | WYETH (US) | 2007-09-27 | — | — | US | disclosed |
| CN-1321984-C | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2007-06-20 | — | — | CN | disclosed |
| CN-1692102-A | Substituted 4- (indazol-3-yl) phenols as Estrogen Receptor (ER) ligands and their use in the treatment of inflammation | WYETH CORP (US) | 2005-11-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225349-A1 | Substituted 4-(Indazol-3-yl)phenols | INSR, TNNI3, INSRR | ESR1 1028/4885MAPK1 857/4885MAP2K4 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.